BioSpace News Archive

Tikcro Technologies Ltd. announced that an Extraordinary General Meeting of Shareholders will be held on Thursday, April 29, 2021 at 9:30 a.m., at the office of Goldfarb Seligman & Co., 98 Yigal Alon Street, Tel Aviv, Israel.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company, and LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, today announced a strategic partnership to develop and commercialize TP-03 in Greater China

Recent FX-322 Study Readouts Support Single-Dose Administration as Part of Future Trial Designs; Company Planning Additional Single Injection Studies Results from Exploratory FX-322 Phase 1b Studies in Patients with Age-Related and Severe Hearing Loss Anticipated in Q2 and Q3 Respectively

Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update.

Initiated SBT6050 clinical development, with pharmacological activity demonstrated in the first dose cohort Advanced preclinical development of SBT6290 and declared SBT8230 as the development candidate for chronic hepatitis B virus program Raised $441.2 million including $277.7 million in gross proceeds from our IPO $386.6 million in cash and cash equivalents at end of 2020

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Cognate BioServices, Inc. for approximately $875 million, subject to customary closing adjustments.

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab TM , today announced that it has commenced an underwritten public offering 5,000,000 shares of its common stock. In connection with this offering, Humanigen expects to grant the underwriters a 30-day option

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 4:30 p.m. Eastern time.

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, is exhibiting on March 30-31, 2021, at the annual Outsourcing in Clinical Trials Southeast.

Stuart Therapeutics, Inc. (“Stuart”), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced that it has been selected as a presenter at the American Society of Cataract and Refractive Surgery (ASCRS) 2021 Annual Meeting,